-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 A4zaMaxQ8wOb/SMDl14ZZRBQNylxXPBw4L5GeIQGvZ2MtecBkyLDJphEiTmhCGOn
 g3TVnyfpMzVaVwyNQyAt1g==

<SEC-DOCUMENT>0001193125-10-179761.txt : 20100930
<SEC-HEADER>0001193125-10-179761.hdr.sgml : 20100930
<ACCEPTANCE-DATETIME>20100805192729
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-10-179761
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20100805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMERICAN VANGUARD CORP
		CENTRAL INDEX KEY:			0000005981
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE CHEMICALS [2870]
		IRS NUMBER:				952588080
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		4695 MACARTHUR COURT
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		9492601200

	MAIL ADDRESS:	
		STREET 1:		4695 MACARTHUR COURT
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AEROCON INC
		DATE OF NAME CHANGE:	19720620
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>Correspondence Letter</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


 <P STYLE="margin-top:0px;margin-bottom:0px">

<IMG SRC="g33836g76z03.jpg" ALT="LOGO"> </P>
 <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">August&nbsp;5, 2010</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">Via FAX and EDGAR</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Securities and Exchange
Commission </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">100 F. Street, N.E. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Washington, D.C. 20549 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Lyn Shenk, Branch
Chief </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Re:</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>American Vanguard Corporation </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Form 10-K </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Filed March&nbsp;10, 2010 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Schedule 14A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Filed April&nbsp;27, 2010 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>File No.&nbsp;01-13795 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">On behalf of American Vanguard Corporation, I am responding to your letter dated July&nbsp;2, 2010 to Eric Wintemute (President&nbsp;&amp; CEO) regarding
the Commission&#146;s review of our filings and provision of comments. We confirm that we will revise our documents in future filings as indicated below and hereby provide responses to the SEC&#146;s requests. For your convenience, we have
re-presented the Commission&#146;s comments in non-italicized font and indicated our answers in italics. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Form 10-K For the Year Ended
December&nbsp;31, 2009 </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operation, page 21
</U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Results of Operations </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We note that certain program payments to customers are classified as a reduction of sales revenues and other payments are classified as operating
expenses and note a discussion on page 23 regarding changes in the portion that is classified as an operating expense. There is no discussion regarding the impact such programs have had on sales revenues. Please revise to provide a discussion
describing the impact that volume or other key </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General Counsel &amp; Secretary ~ American Vanguard Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949) 221-6115 ~ timd@amvac-chemical.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
performance indicator driven payments, or other program costs, have had on revenue. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: The Company has two types of programs. The first type of program involves reimbursing customers for the approximate
value of expenses that would otherwise be paid by the company for activities such as training, product stewardship and promotion. This type of program is accounted for as an operating expense in accordance with FASB ASC 605-50-25, &#147;Customer
Payments and Incentives.&#148; </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The second type of program involves price concessions, rebates or purchase credits
related to things such as volume purchases, early ordering and the like. This type of program does not involve the provision of services by the customer and is accounted for as a reduction against gross sales. Programs are considered normal course
of business within our sector. Competitors offer programs to induce sales, and buyers expect that sellers will offer such program pricing. We can say this much&#151;without programs, we would not be competitive. That is, we would lose market share
in virtually all product lines. Having programs tends to have a positive impact on sales; however, we cannot say how much of an impact. This is so for a number of reasons. First, customers make their procurement decisions based upon many factors
(including product efficacy, quality, customer service, personal relationships, advertising, and pricing) of which programs are only one. Second, the level of sales from year to year for each product are subject to many other factors entirely
outside of the buyer&#146;s or seller&#146;s control, e.g., weather, pest pressure, technological competition. Third, the level of programs relative to net pricing (the price after programs) varies by product, by year (or partial year) and often by
geography. For these reasons, we are not able to describe the impact of programs on our sales with greater certainty. </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>In effect, we employ programs as a means of meeting the competition in a very fluid environment. We can say that, in general, more
generous programs tend to bring on greater sales; however, overly generous programs can reduce margin dollars to lower levels. Insofar as we have managed to maintain a fairly consistent gross margin over the past few years, we believe that we are
managing our programs well. </I></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We note that tolling activities lowered gross profit in 2009 and the first quarter of 2010. Please provide a discussion explaining the nature of these activities and
quantify the impact they have on gross profit. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: In our MDA comments in the 10-K and the 10-Q we
use the term &#147;tolling activities&#148; to describe the few large contracts we have agreed to manufacture either base or intermediate materials for other agricultural chemical companies. Tolling is a term that is regularly used in the industry
and we believe that it is a </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General Counsel &amp; Secretary ~ American Vanguard Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949) 221-6115 ~ timd@amvac-chemical.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
concept understood by our investors. Generally speaking these transactions are entered into (by us) with a view to covering manufacturing site overhead. Accordingly, we accept lower average
prices and margins in order to effectively compete with alternative sources outside the mainland USA. In FY 2009, we made sales in the amount of $6.2MM of this kind of transaction and earned 14% margins. In FY 2008 we had lower sales amounting to
$4.2MM and earned 18% margins. In Q1 of 2010 and again in Q2 of 2010, we have seen lower levels of these type of sales in comparison to prior year. Overall for year to date 2010 we have recorded sales of $1.0MM at a margin of 18% as compared to the
prior year in which we recorded sales of $4.1MM at a margin of 17%. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The impact of tolling for both FY 2009 and FY 2008
on overall gross margin was about 0.5%. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>As a business, we manage this activity along side a grouping of other product
lines with comparatively small annual sales levels. These include our Plant Growth Regulators and our Granulated products. We will adjust our next filing to comment on this activity as a part of our &#147;Other&#148; sales activity. Furthermore,
tolling activity does not have a material impact on gross margin every quarter; however, in future filings when the impact is material, we will expand our disclosure. Tolling activity did not have a material effect upon gross margin in Q2 2010;
thus, we believe that additional disclosure is not warranted in the MD&amp;A of the Form 10Q for the period ended June&nbsp;30, 2010. </I><B><I></I></B><I> </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Critical Accounting Policies, page 31 </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">This section should include the identification of the accounting estimates reflected in your financial statements that require assumptions on uncertain items and whose
changes could materially impact the company&#146;s financial condition or changes in operations. In this regard, we note the recent $13.5 million charge recorded to adjust inventory values. As estimates for inventory obsolescence and valuation
require assumptions that are uncertain, please revise to disclose the methodology and assumptions underlying these estimates and the impact of any changes in the estimates. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: As detailed in the 10K for the year ended 2009, the company values its inventories at lower of cost or market.
Furthermore, the company writes down and makes adjustments to its inventory carrying values as a result of the effects of unutilized capacity, net realizable value and assessments of slow moving and obsolete inventory and other annual adjustments to
ensure that our standards continue to closely reflect actual cost. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Business management considers several factors when
assessing net realizable value of inventory. These include current quantities on hand, actual sales for the last year and forecasted sales for the next year for each specific inventory line
</I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General Counsel &amp; Secretary ~ American Vanguard Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949) 221-6115 ~ timd@amvac-chemical.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
item. We look at the carrying value of our inventory in comparison to prevailing market pricing and preferred packaging or formulations based on information from our field sales people. We also
take into account information on label status from our regulatory group covering domestic and foreign product registrations. </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Our business is subject to a range of risks which can impact demand for our products. These risks are common to companies in our
Agricultural sector. The major risks that affect demand for our products include weather, localized pest pressure, the entry into the market of competitive new products, decisions of the EPA or foreign equivalents, and changes in customer buying
patterns (for example impact of credit availability). All these factors can impact future demand for our products and inventory. </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Management estimates of the net realizable value of our inventory are updated on a quarterly basis and if appropriate adjustments are
made to the carrying value with the consequent charge recorded as an additional cost of sales. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>We have added the
following paragraph to our Form 10-Q for the period ended June&nbsp;30, 2010 (under &#147;Critical Accounting Policies and Estimates&#148;) and will expand the MD&amp;A within our Form 10-K for the period ending December&nbsp;31, 2010 in a similar
manner. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>&#147;Inventory net realizable value</I></B><I>&#151;We value our inventories at the lower of cost or
market. Cost includes the raw material purchase cost, any freight, insurance and duties involved in getting our inventories to the point of manufacture, labor and manufacturing overhead incurred in our factories and any third party contract
manufacturing. Based on a consideration of quantities on hand, recent actual historical sales and medium term future sales projections, latest information on labels from the EPA or similar foreign agencies, market pricing and particular formulation
preference intelligence garnered from the market by our field sales and marketing teams, slow moving and obsolete inventory is written down to its net realizable value. </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Failure of management to correctly estimate the impact of the factors detailed above will affect managements estimates used in
establishing our inventory carrying values. These estimates are monitored on a quarterly basis and when necessary adjustments are made to reflect net realizable value. Any adjustments of this kind are recorded as an increase to cost of goods
sold.&#148; </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General
Counsel &amp; Secretary ~ American Vanguard Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949)
221-6115 ~ timd@amvac-chemical.com </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Accrued Program Costs </U></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We note that each quarter you estimate the current liability associated with accrued program costs due to distributors and retailers at the end of a growing season.
Please expand to explain what is meant by &#147;management applies experience and market place knowledge&#148; to more fully explain the assumptions and methodology underlying these estimates and the impact of any changes in such estimates.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: On a monthly basis, the company makes adjustments to the accrual based on the actual
transactions compared to the published programs. Each period we also use management estimates/assessments to make forecasts as to whether each customer will fully comply with all of the terms of the program &#150; including, for example, annual
volume take up, advertising, and product stewardship activities. If we believe that the customer will not fully satisfy all program requirements, then we make periodic adjustments by reversing some of the accrual to reflect our best estimate of the
likely, final settlement to such customer at the particular balance sheet date. The following paragraph is included in our Form 10-Q for the period ended June&nbsp;30 2010 (under &#147;Critical Accounting Policies and Estimates&#148;):
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#147;</I><B><I>Accrued Program Costs</I></B><I>&#151;The Company has adopted FASB ASC 605 [Emerging Issues Task Force
Issue No.&nbsp;01-9, Accounting for Consideration given by a Vendor to a Customer or Reseller of the Vendor&#146;s Products (&#147;EITF 01-9&#148;)]. In accordance with ASC 605, the Company classifies certain payments to its customers as a reduction
of sales revenues and other payments as operating expenses. The Company describes these costs overall as &#147;Programs&#148;. Programs are a critical part of doing business in the agricultural chemicals business place. The type of programs treated
as a reduction in sales are market pricing adjustment, volume take up or other key performance indicator (&#147;KPI&#148;) driven payments made to distributors or retailers at the end of a growing season. The type of programs treated as operating
expenses are effectively re-imbursement of costs for activities such as advertising, training, and other product stewardship type costs that we would otherwise spend ourselves (and report as operating expenses). Each quarter management compares each
sales transaction with published programs to determine what program liability has been incurred. Once this initial calculation is made for the specific quarter, sales and marketing management along with executive and financial management review the
accumulated program balance and make assessments of whether or not customers are tracking in a manner that indicates that they will </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General Counsel &amp; Secretary ~
American Vanguard Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949) 221-6115 ~
timd@amvac-chemical.com </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
meet the requirements set out in the terms and conditions attached to each program. This includes customer activity relating to such things as annual volume take up, product line advertising and
stewardship. If management believes that customers are falling short of their annual goals, then periodic adjustments will be made to the accumulated accrual to properly reflect the Company&#146;s best estimate of the liability at the balance sheet
date. Programs are paid out predominantly on an annual basis, usually in the first quarter of the financial year, though significant payments can also occur in the final quarter of a financial year.&#146; </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Note 6: Major Customers and Export Sales, page 63 </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Please revise to disclose revenues from customers for each group of similar products or product lines (such as cosmetic, pharmaceutical, nutritional, etc. or herbicide,
insecticide, etc.) in accordance with ASC 280-10-50-40. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: In future filings we will disclose
revenues for categories of products as management are increasingly using to manage the business as follows: we will continue to report on the crop and non-crop segments and within the crop segment, we will disclose revenues for the following
categories: i) insecticides, ii) herbicide/fungicide/soil fumigants, and iii) other (including, for example, plant growth regulators, tolling arrangements). </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Form 10-Q for the Quarterly Period Ended March&nbsp;31, 2010 </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Consolidated Balance Sheets </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We note that accrued program costs decreased significantly from December&nbsp;31, 2009 to March&nbsp;31, 2010. Please tell us why this liability
decreased and, if such a decrease continues for the quarter ended
June&nbsp;30</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">, please revise your next filing to discuss.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: The majority of the company&#146;s program run on a 12 month basis typically following the
calendar year. Thus, the historical trend is for accruals to build over the course of Q2 through Q4 and to be settled and paid out either during the course of Q4 or Q1 of the immediately following year. In the case of FY2009, the accruals peaked in
Q4 and were predominantly settled and paid out in Q1 of 2010. During Q2 of 2010, the program accrual will show an increase relative to the balance held at the end of Q1 2010. The company has included a discussion of this issue in the Liquidity and
Capital Resources section of our Form 10-Q for the period ended June&nbsp;30, 2010 and will make similar disclosures in future filings. </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General Counsel &amp; Secretary ~ American Vanguard Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949) 221-6115 ~ timd@amvac-chemical.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Definitive Proxy Statement on Schedule 14A </U></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Common Stock Ownership of Certain Beneficial Owners, page 12 </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the table on page 13, we note that you reference footnote 7 Carl R. Soderlind&#146;s beneficial ownership. Footnote 7, however, describes John B. Miles&#146;
beneficial holdings. If you have omitted material information regarding Mr.&nbsp;Soderlind&#146;s common stock ownership, please revise in future filings. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: The footnote 7 reference was juxtaposed with Mr.&nbsp;Soderlind&#146;s name erroneously. We will delete that footnote
from his name in future filings. No material information regarding Mr.&nbsp;Soderlind&#146;s common stock ownership was omitted. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Compensation and Discussion Analysis, page 14 </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">8.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We note your disclosure on pages 15 and 16 that you benchmark your ten most highly paid executives against public companies having annual revenues of between $225
million and $400 million and that you benchmark similarly situated companies as to the prevalence of equity awards and total compensation among senior executives. Please confirm that in future filings you will identify the companies to which you
benchmark and disclose the degree to which the compensation committee considers such companies comparable to you. Refer to item 402(b)(2)(xiv) of Regulation S-K. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: We confirm that in future filings we will identify the companies to which we benchmark executive compensation and will
disclose the degree to which the compensation committee considers such companies comparable to us. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><U>Grants of Plan Based Awards, page
22 </U></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">9.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We note that column l of your table on pages 22 and 23 shows the full grant date fair value of restricted stock grants made based on the closing price of your common
stock as of the date of grant and that you disclose that the closing price was $11.73 per share. We also note that Mr.&nbsp;Thorley&#146;s grant date was two months and one day prior to the other named executive officers. Please confirm that the
closing price on both grant dates was $11.73 per share. </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I><U>Answer</U>: The closing price on grant dates for
all persons in the table except Mr.&nbsp;Thorley was in fact $11.73. The closing price on the grant date for Mr.&nbsp;Thorley was $11.98. The note, therefore, is in error, and will be corrected in future filings. </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General Counsel &amp; Secretary ~
American Vanguard Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949) 221-6115 ~
timd@amvac-chemical.com </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The company hereby acknowledges that: </I></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the company is responsible for the adequacy and accuracy of the disclosure in the filing; </I></FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to
the filing; and </I></FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>&#149;</I></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><I>the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States. </I></FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Please let me know if you require further clarification on any
of these issues. I can be reached at 949.221.6115, fax &#150; 949.476.2471, or timd@amvac-chemical.com. </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Regards, </I>
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/&nbsp;&nbsp;T<SMALL>IMOTHY</SMALL> J. D<SMALL>ONNELLY</SMALL> </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Timothy J. Donnelly </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Chief Administrative Officer, </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>General Counsel&nbsp;&amp; Secretary </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>American Vanguard Corporation </I></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Timothy J. Donnelly ~ CAO, General Counsel &amp; Secretary ~ American Vanguard Corporation </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">4695 MacArthur Court, Suite 1250, Newport Beach, CA 92660 ~ (949) 221-6115 ~ timd@amvac-chemical.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g33836g76z03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g33836g76z03.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`.@#;`P$1``(1`0,1`?_$`)\``0`"`@,!````````
M```````$!@,%`0<(`@$!``,!`0$```````````````$#!`(%!A```00!`@0$
M`P,)!`L``````@$#!`4`$08A$A,',4$B%%%A,G&A4H&1<K(C,Q46"+%"8J+!
MT9+"TF/3)#0F%Q$!``(!!``$!`4%`0````````$"`Q$A,01!41(%<2(R%6&1
M0E(3@:&QT3,4_]H`#`,!``(1`Q$`/P#TM?WL:DKRG2&S<;'Q%M$4OOTRS#BG
M);2%>3)%(UEUO+_J.VK&<4#K)Y:+IJ*-?Z33/0^TY/.%%>W6?!%7^I_9?@M9
M9(OZ+/\`U<?:,OG"S_T5=OQ9(2([3XZB+H"X*%XHA)JFOY\\N8TG1=JS:IA)
MK@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@5+N:2)MAW754U\OLS;[?_`-&3
MN_0\G7*JKQJJ+HBY]/5Y^)'D;>M6Z7^-OMBU7$\L4'#,4,GD#J*"-\2^GCQS
MF,M9MZ8Y:=-M7MFH%%JXB?!AK]1,^/O]4_%Z$<0DDT6NH%R_V9&I-6$I+C*Z
M/!Z/QCQR?3KPYF\QRSMO-.)JV2$GRSF=G<6B>'WJF$F`P&`P&`P&`P&`P&`P
M&`P&`P&`P&`P*GW*!3VVX.J#Q55(N""B)XJOPS;T)TR,?=CY'E^?`$$D3`=!
MU6R4(S>A"INZ<Q$*$GJ1H?5]NF?1^KP>?BEEWJBPME;0IU5>J\Q)N)/'55.8
M[RMJOQ7IMY3U]\M[?T_)MM],0[LW;WGE[1D2(#.WSLXM-60+&REA)!E08E.>
MWT!LA7G-"1-$UX_+/EK<S\6Z.(99'?7V-)</VE&4.[JK6/3)6K*;-HWY@"ZP
M92D%!`.F2D:\J\NGGD)82[[/.T-;+A[;=G6UC;/47\,:DM\GNFFE=0VI!"(.
M,F*(J'HG!?E@8;3N"]2V>])+PR77:9ZIC0ZH29Y2DV3(\K+)B(JB*Z?J)Q2^
M7#AEM<GA.ZFV+QC9.L.[^X:3;YR[S:YP;<)B04B/RVFHZZIS(^DHDT-K3S$%
M+7AID_Q:QK"8OOI+B/WR>L:O;$BCV\Y83]SMSR8A+*:91ERN_>H;I"J**Z+H
M6GPX<<IG9:O&Q]UQMV[3K=QQF3C,V3/52.XJ*8*A*!"JIP70A7CYX'6V^.X>
M\=MW.\J4)*.S9,:M?V2)-MZBY/>]DX&G+^TZ;_K]6O#`W3G=TJS>L#9T^`KR
MO2&:PK7W,='G)1L=3J^R#5P624=.=>7CX#I@?&W>]PV][607Z"1`K;B380(-
MJ;S3@E)K>=715H?6@*#2JAKY\-//`^=N]\$N;.I87;LN)7;@;G2*.R<=:('X
M\!M3(R;%>=LCT](KY*BZX$^C[Q5]L-$05LAM+RFDWC8H0$0-Q"$29T]/,9<_
M#BB8&DC?U#UI46X+.53.M/;?:AR7H<>3'EJXS/>1EO1QE5`70+ZVU\/#7`^-
MZ=Z;^#2SX];MN8QN"-2O6\X7"8+^&@I.-QB>%5T=(B;YR`?`?C@=G;9FR)VV
MZJ;))"DRH<=Y\D1$13<:$B5$3PXK@=;V-]W.W+NO=,7:=M#IX>TC9CLQI4='
MDG2C91\TD.*O,RTB%RHH<?/`V.X^\#M"^40Z)^TDU=<S:[H=@NM]&"PZB^IM
M7%$GU]!D@CIZ4UP)2=VX[^[)-#7U$J;'AP6K.7;@38QVXTB,<AI20EY^8^1`
M%-//7P3`UVV^^U=9=!VTI9E)`G53]W63)!-.#(C1!0Y.@MDI"H(NH\WU)QX8
M'-;WQCOQ9K]E03:D@IWMPU3<@V26;7LIJ1"H$O2<T(5Y"\EP.)W>QV)M.NW"
MYMJ4P-J3AQ(\R3%B_P#;-M(\CQN.'RIU17]FVFI%\L#B%W8M+;>FV(57`_\`
M7-PT3UPLEU120VHJ/+Z>;P#F02'1=575%T1<"+0=Y)9[2VL3%=,W-N2]B2)R
M1F4CQ3]O%<4'7G-2Z0>*"(C]2X$J=WWKUBU3]'1S;HK>K?N&&FR99)MB(:`^
M+W5).4@75.&NJ\//`G__`&_:'3ZG3E<O\M?S=KTQ_P#!ZG3Y/J_>\WEX?/`V
M_<=DY.WSBMZ=9]4!I%71%-?`=?GFSHSI?6>(9>W$S72'E[<Z-A;LP6W.G'KU
M1KJ%S(A&A<SSO!%7U%X?)$SZ3'QKYO/QL7<VWJ[C=12*EU#J8\>/#KTT(51J
M.T(<1)!4=2UROJ8[4Q_-]6\RUWMK+TQ:=JMK[C9G2+%9*.7=;$KIW2=0$Z$5
MSKM\GI7E+G\5^&?*6YGXMT<,MEVEVK8!<=4I0/W,V-9.RFGN1UB7#`6V78Y(
MGH44#SUR$ON+VMH&6ZA'94^9(IK`[9F7*D*Z\[*<`FR)XB3B/*6B"*"B8'-O
MVJVM:EN$I?N%/<KD1Z<8.\I-NP!08[D=435L@Y47SXX&MD]D]LR*IB&]/LW)
MD>P6V&X.0AS%E$'2(E,A4.7D]*"@:)Y<<ZBVDHF-6C;[21-K.54JL>DO-T?O
M$@NFXA$(S]>LCJ<OJ\>"YLQ6I>(K/+)EB])F8\6\[?V=)MC;L';:(XU$@`K;
M#YKU-4(U-5-41/,OAD9.G,;UW*=N/U;-Q=[#VMN7<=!NF4A.SJ`C<KW&C3IE
MU$14ZB:+S()(A#\%S%,3'+7$Q.\-4O9K;B[I/<(S9P.':-W?L1<!(WO@#IJX
MJ<G.2$'#E4]$\M,)2ZWM/MJO*E)AR22T4Z=8PD,Q5%>L4<1Y'/2FH_MBY4X8
M%`V)VAW37[[K9UC$&!04(6+42,EB<U@QGIR"W$8)L"CMHBJ1<Y*OEX)@6>E[
M![8K$)LK.SF1DKIE-&C2'@5MB!.5%-IKE`511TX$JZ_'`QQ.P&W&JFQKI%I8
M2QM(D*#(=<5@%%FN>1Z.C0MM`(Z::+PX^/C@;;>W:.HW59.SW+.?5NS()5=H
M,!P`&7$U(A;=YP<^DC7B.G!=/#`N-9`:KJV)7LJ1,PV6X[9%Q)1:!`15T\]$
MP*/NGLS3WUS/LFK:RJ`NFVV=PPJ]X6V9[;0\@HZA"2B7)Z%(%15'`;F[+;>N
MI(N1YTZGCO0FJJSAU[@@U,@,:HVP[SB:H@B2CS"J+RKI@;-.W];7RMPV=8II
M+NJYBN2*1(C(!#9-IA`X:I^\XZK@4'9W;*KVM14Q[RFR[2X*J*DAT!N`^VTD
MH424S$%H1(D-!XD1*@CYHF=TI-N/!S:T0L51V0I(T.>S+MK*Q655.T4(ICC9
ME!KGDT)ACE`4UX)ZRU7@F<.DW<?:"GNXVW6?XC+A'MR,<&*^QTE,X[K(L."2
M.@X*$0MIZQ1%3RP/NJ[25-9*VQ)BV$L7-L0':IE-6^61%=1$4'DY/)1%=1T\
M,""79"G9I**!57%A4SMOL/1(=O%-M)!1I)<[S3G,!`0DO%/3P7BF!/A]H-LP
M2K_8N/QV:VGDT4=I"$D5B62&XZ2JFJN<PZZ^''PP-;_\(VWT>E[^7I_*_P#)
M^NK>OL^KU>M]/[W7A\/E@;ON>\XUMITFU03)%1"\T11XZ9M]OC6['W9TK#RA
M<O.$[H9$7+]**JJB)\$USZ>K!BAIE71T43S7CG4\-,0]Y04TAL)_RP_53/BI
MY>C#-D),!@,`J(J:+@5N^V;$FB;L31B47'3CR$OS1/#\F:L/;FFT[PRY>K%N
M-I41Q_<6VI2BA%')2^A4YFC1/MU%<]'3'FCS8OGQ2L]/W/KG$%FU#VCJ\.L.
MI-*OZPYDR]"T;UW:L?=B=K;+C&F1I32/1G@>:7BAMDA)^=,P368VGELBT3O#
M/D),!@,!@,`N!3MS;\5B?_+VW&!M]SNIK[<5_811\.K+<3Z!3\/U+FG%U]8]
M=_EI_GX*[9-](Y3=K[22N=.SLY*V>X90(,NQ--$0?'HL!X--)^%/'Q7.,N;U
M;5CTTCP_W^)2FF\\K(B92L,!@,!@,"':4]=:1EC3F4>97Q%55/[%3.\>2U)U
MK.CB^.MHTE4I'9;MN^JDY4#JOFCKR?[V:?N&?]RJ.M2$,^PG;`B0OX68JGAI
M(>_XLZ^Y9_-U_!5V&V`@`@/TBB(GV)PS"N?6`P&`P&`P(\V#$F,$Q*:%YHO$
M#35,FMIK.L;2BU8F-)4+</;$B17:AQ%XZ^U=7X?A/_7GI8?</"_YL&7I>-5!
M?+<.W9Q"V;]<^GDFHH6GP_NDF>C$8\L>%H8H]=)\I;^M[SW$5$&TC-2P3Q<;
M56G-/T=%%?NS+D]LK/TSHT4[UHYC5;:OO#LJ9RB])."Z7]V0"H/^V/,.8[^W
MY:\1JU4[E)YV62'N.BGIS0K&-(3SZ;H$OYM<RVPWKS$PT5RUGB83T?:TUYQ5
M/CJF5Z2ZUA'E6U;%;5R3+88!/$G'`!$_.N=5I:>(1-HCQ4V][W=O:E#%+'W[
MX)KTH8JZBK\.IP;_`,V:L?M^:_AI'XJK=BL*Y$W#W+[C*@U#2[7VR:JCMD7J
MDNAX:-*J#Q7_``\/\6:+8L/7^J?7?R\'$7ODXVAV)M+9U%M>N]E5L<O.O/)D
MFO,\^YYFZ:\27,&;/;);6R^E(K&S>HFF5.S`8#`8#`8#`8#`8#`8#`8#`8#`
M:)@1Y<&)+9)F4R#S1:HH&*$G'[<FMIKO&SFU8M&DJ7;]H-MS$58A.P'%XIR+
MSAK^B>OW+F['[EDKSNRWZ5)XV4FU[';C!%6%*CR_@BJ31+Q^:*GWYNI[I3]4
M3#+;HWCC257E]I-^-%HE43BIPYFW&R1?\R9ICW##^Y5/6R>3`UVD[B/ER#6.
M-)^)QT!']9<3[AA\W5>MD\FXKOZ=-SRM"LIT:$/F@\T@]/R<@_?E%_=L<?3$
MS_9?7J7\=G8NU>QVR:%P)+C!6DX%YA>F:$(DGF+2>A/RHN>=G]QRY-HGTQ^#
M73KUKSN[#011$1$1$3@B)Y9A7N<!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
7!@<+X9$CE,0&2&`P&`P&`P&`P&!__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
